CollabRx ONE, TREAT1000: The Cancer Connection

CollabRx was set up by Jay “Marty” Tenenbaum and Raphael Lehrer to slash the cost and time of developing drug therapies (see “Collaboration and the Long Tail of Disease,” Bio•IT World, March 2009). Its new service, CollabRx ONE, applies those resources to help identify bespoke therapies for late-stage cancer patients. The goal of the service, which costs between $50-100,000, is to provide a deep understanding of the individual patient’s disease by marrying genomic and computational analysis, and match the aberrant target or pathway with a potential therapy.